Minoryx Therapeutics, S.L.   Report issue

For profit Phase 3
Founded: Barcelona Spain (2011)

Organization Overview

First Clinical Trial
2017
NCT03231878
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Minoryx Therapeutics, S.L.

Active Ingredients

Drugs in Phase 3 Trials (1)

Leriglitazone (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adrenoleukodystrophy (Phase 3)

Ataxia (Phase 2)

Cerebellar Ataxia (Phase 2)

Disease Progression (Phase 2)

Friedreich Ataxia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 1